Any peptide experiment, limited to those with a genuine anti-inflammatory rationale like KPV, would sit on top of proven treatment, never in place of it, and never including LL-37
Yeast infections, particularly vulvovaginal candidiasis and candidal balanitis, are not listed as recognized adverse effects specific to these medications in clinical trials or post-marketing surveillance data
Market is driven by a high level of innovation and high clinical adoption of GLP-1 therapies
Written informed consent was waived by the IRB due to the retrospective nature of the study
This scale of need drives many patients to explore every available option from prescription medications to non-surgical treatments like lipotropic injections
Once critical early signals are identified, pharma companies can make more informed decisions around field deployment, health system prioritization, distribution planning, and access strategy